Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARA NASDAQ:ENTX NASDAQ:GNLX NASDAQ:SKYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsENTXEntera Bio$2.41+1.3%$1.98$1.50▼$2.95$108.68M1.68140,472 shs86,113 shsGNLXGenelux$5.36-1.5%$4.00$1.99▼$5.89$205.49M-0.22138,864 shs171,138 shsSKYESkye Bioscience$1.45-5.2%$3.37$1.14▼$5.96$47.41M2.341.78 million shs723,606 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%0.00%+73.86%ENTXEntera Bio-6.30%+9.68%+30.05%+16.67%+31.49%GNLXGenelux+3.03%+14.53%+38.78%+60.00%+70.53%SKYESkye Bioscience+0.66%-11.05%-62.41%-58.87%-63.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsENTXEntera Bio$2.41+1.3%$1.98$1.50▼$2.95$108.68M1.68140,472 shs86,113 shsGNLXGenelux$5.36-1.5%$4.00$1.99▼$5.89$205.49M-0.22138,864 shs171,138 shsSKYESkye Bioscience$1.45-5.2%$3.37$1.14▼$5.96$47.41M2.341.78 million shs723,606 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%0.00%+73.86%ENTXEntera Bio-6.30%+9.68%+30.05%+16.67%+31.49%GNLXGenelux+3.03%+14.53%+38.78%+60.00%+70.53%SKYESkye Bioscience+0.66%-11.05%-62.41%-58.87%-63.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 0.00N/AN/AN/AENTXEntera Bio 2.50Moderate Buy$10.00314.94% UpsideGNLXGenelux 2.50Moderate Buy$20.33279.35% UpsideSKYESkye Bioscience 2.57Moderate Buy$9.80575.86% UpsideCurrent Analyst Ratings BreakdownLatest CARA, GNLX, SKYE, and ENTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ENTXEntera BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025GNLXGeneluxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SKYESkye BioscienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025SKYESkye BioscienceCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$2.0010/6/2025SKYESkye BioscienceCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$2.009/30/2025SKYESkye BioscienceHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.009/27/2025ENTXEntera BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GNLXGeneluxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SKYESkye BioscienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)8/15/2025SKYESkye BioscienceEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/14/2025SKYESkye BioscienceEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.00(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00ENTXEntera Bio$180K611.34N/AN/A$0.23 per share10.48GNLXGenelux$10K20,244.72N/AN/A$0.76 per share7.05SKYESkye BioscienceN/AN/AN/AN/A$2.25 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/AENTXEntera Bio-$9.54M-$0.26N/AN/AN/A-4,525.11%-77.75%-68.13%11/14/2025 (Estimated)GNLXGenelux-$29.87M-$0.86N/AN/AN/AN/A-107.47%-83.14%11/13/2025 (Estimated)SKYESkye Bioscience-$26.57M-$1.060.00N/AN/AN/A-76.03%-69.20%N/ALatest CARA, GNLX, SKYE, and ENTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025N/AGNLXGenelux-$0.23N/AN/AN/AN/AN/A8/8/2025Q2 2025ENTXEntera Bio-$0.11-$0.06+$0.05-$0.06N/AN/A8/7/2025Q2 2025GNLXGenelux-$0.22-$0.20+$0.02-$0.20N/AN/A8/7/2025Q2 2025SKYESkye Bioscience-$0.34-$0.44-$0.10-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71ENTXEntera BioN/A10.4710.47GNLXGeneluxN/A4.184.18SKYESkye BioscienceN/A6.096.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%ENTXEntera Bio14.11%GNLXGenelux37.33%SKYESkye Bioscience21.09%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%ENTXEntera Bio10.38%GNLXGenelux8.80%SKYESkye Bioscience4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableENTXEntera Bio2045.66 million40.92 millionOptionableGNLXGenelux1037.77 million34.45 millionNot OptionableSKYESkye Bioscience1130.99 million29.59 millionOptionableCARA, GNLX, SKYE, and ENTX HeadlinesRecent News About These CompaniesSkye Bioscience (SKYE) was downgraded to a Hold Rating at Craig-HallumOctober 14 at 5:50 PM | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYEOctober 13 at 2:00 PM | prnewswire.comNew obesity drug boosts GLP-1 weight loss without added side effectsOctober 12, 2025 | newatlas.comNSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Rating of "Moderate Buy" from BrokeragesOctober 11, 2025 | americanbankingnews.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 11, 2025 | marketbeat.comFY2026 EPS Estimate for Skye Bioscience Lifted by AnalystOctober 11, 2025 | americanbankingnews.comFY2026 EPS Forecast for Skye Bioscience Raised by AnalystOctober 10, 2025 | marketbeat.comSkye Bioscience’s Weight Loss Drug Underwhelms in Phase 2 TrialOctober 9, 2025 | medicalherald.comMWeiss Ratings Reaffirms "Sell (D-)" Rating for Skye Bioscience (NASDAQ:SKYE)October 9, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYEOctober 8, 2025 | prnewswire.comSkye Bioscience (NASDAQ:SKYE) Stock Rating Lowered by Cantor FitzgeraldOctober 8, 2025 | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Stock Rating Lowered by Craig HallumOctober 8, 2025 | americanbankingnews.comSkye Bioscience announces topline CBeyond phase 2a data from nimacimab monotherapy and combination clinical trialOctober 7, 2025 | pharmabiz.comPSkye’s CB1 Inhibitor Shows ‘Intriguing Synergy’ With Wegovy, Despite Mid-Stage Obesity FailOctober 7, 2025 | biospace.comBWhy Skye Bioscience (SKYE) Is Down 51.0% After Releasing Phase 2a Nimacimab Trial Results and What's NextOctober 7, 2025 | finance.yahoo.comSKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II GoalOctober 7, 2025 | zacks.comSkye’s obesity drug stumbles alone but shines in combo with WegovyOctober 7, 2025 | thepharmaletter.comTSkye’s shares crash down to earth on Phase II obesity lossOctober 7, 2025 | finance.yahoo.comSkye's obesity drug misses mid-stage trial main goal, shares tankOctober 6, 2025 | msn.comSkye Bioscience Shares Plunge After Weight Loss Drug Fails Mid-Stage TrialOctober 6, 2025 | msn.comSkye shares crash as obesity drug falls short in key studyOctober 6, 2025 | biopharmadive.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCARA, GNLX, SKYE, and ENTX Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Entera Bio NASDAQ:ENTX$2.41 +0.03 (+1.26%) Closing price 04:00 PM EasternExtended Trading$2.41 0.00 (0.00%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Genelux NASDAQ:GNLX$5.36 -0.08 (-1.47%) Closing price 04:00 PM EasternExtended Trading$5.50 +0.14 (+2.59%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Skye Bioscience NASDAQ:SKYE$1.45 -0.08 (-5.23%) Closing price 04:00 PM EasternExtended Trading$1.47 +0.02 (+1.38%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
